Publications by authors named "Alessandra Beano"

Claim this Profile
A
A Phase 2, Open Label, Multicenter, Single Arm Trial Evaluating the Activity and Safety of Abemaciclib + Aromatase Inhibitors (AIs) as Second-Line Treatment After First-Line Fulvestrant in Hormone-Receptor-Positive (HR+), Human-Epidermal-Growth-Factor-Receptor-Negative (HER2-) Metastatic Breast Cancer (MBC) Patients. Final Results of HERMIONE-7 Trial.
Cazzaniga Marina Elena, Pepe Francesca Fulvia, Rossi Emanuela, Coltelli Luigi, Beano Alessandra

Clin Breast Cancer· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
STAT3 expression in brain metastases from breast cancer is correlated with molecular subtype and impacts clinical outcome.
Alessia Pellerino, Neibla Priego, Luca Bertero, Alessia Andrea Ricci, Luca Mangherini, Alessandra Beano

Neuro Oncol· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Survival Outcomes of Luminal Metastatic Breast Cancer Patients According to Changes in Molecular Subtype at Re-Biopsy: Insights from the GIM-13-AMBRA Study.
Marina Elena Cazzaniga, Paolo Pronzato, Domenico Amoroso, Grazia Arpino, Francesco Atzori, Alessandra Beano

Cancers (Basel)· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[Patient with TNBC with early relapse within 12 months from adjuvant treatment.].
Alessandra Beano

Recenti Prog Med· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Author Correction: Real-world ANASTASE study of atezolizumab+nab-paclitaxel as first-line treatment of PD-L1-positive metastatic triple-negative breast cancer.
Alessandra Fabi, Luisa Carbognin, Andrea Botticelli, Ida Paris, Paola Fuso, Alessandra Beano

NPJ Breast Cancer· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical Outcomes of HER2-Negative Metastatic Breast Cancer Patients in Italy in the Last Decade: Results of the GIM 13-AMBRA Study.
Marina Elena Cazzaniga, Paolo Pronzato, Domenico Amoroso, Antonio Bernardo, Laura Biganzoli, Alessandra Beano

Cancers (Basel)· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Nine-Week Versus One-Year Trastuzumab for Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: 10-Year Update of the ShortHER Phase III Randomized Trial.
PierFranco Conte, Giancarlo Bisagni, Federico Piacentini, Samanta Sarti, Santino Minichillo, Alessandra Beano

J Clin Oncol· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of Caloric Restriction in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy: A Prospective Case Control Study.
Isabella Castellano, Francesco Gallo, Paola Durelli, Taira Monge, Maurizio Fadda, Alessandra Beano

Nutrients· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Author Correction: Real-world ANASTASE study of atezolizumab+nab-paclitaxel as first-line treatment of PD-L1-positive metastatic triple-negative breast cancer.
Alessandra Fabi, Luisa Carbognin, Andrea Botticelli, Ida Paris, Paolo Fuso, Alessandra Beano

NPJ Breast Cancer· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world ANASTASE study of atezolizumab+nab-paclitaxel as first-line treatment of PD-L1-positive metastatic triple-negative breast cancer.
Alessandra Fabi, Luisa Carbognin, Andrea Botticelli, Ida Paris, Paola Fuso, Alessandra Beano

NPJ Breast Cancer· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Validation of the AJCC prognostic stage for HER2-positive breast cancer in the ShortHER trial.
Maria Vittoria Dieci, Giancarlo Bisagni, Alba A Brandes, Antonio Frassoldati, Luigi Cavanna, Alessandra Beano

BMC Med· November 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Dilemma of HER2 Double-equivocal Breast Carcinomas: Genomic Profiling and Implications for Treatment.
Caterina Marchiò, Patrizia Dell'Orto, Laura Annaratone, Felipe C Geyer, Tiziana Venesio, Alessandra Beano

Am J Surg Pathol· September 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Demographic, tumor and clinical features of clinical trials versus clinical practice patients with HER2-positive early breast cancer: results of a prospective study.
Grazia Arpino, Andrea Michelotti, Mauro Truini, Filippo Montemurro, Stefania Russo, Alessandra Beano

J Cancer Res Clin Oncol· March 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Trastuzumab with either docetaxel or vinorelbine as first-line treatment for patients with HER2-positive advanced breast cancer: a retrospective comparison.
Stefania Redana, Michela Donadio, Franco Nolè, Maria Elena Jacomuzzi, Alessandra Beano

BMC Cancer· February 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correlation between NK function and response to trastuzumab in metastatic breast cancer patients.
Alessandra Beano, Elena Signorino, Andrea Evangelista, Davide Brusa, Marinella Mistrangelo

J Transl Med· May 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis